Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
Clinical trial NCT00944034 · COMPLETED
Trial details
- NCT number
- NCT00944034
- Sponsor
- Novartis Vaccines
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2009-07-01
- Primary completion
- 2011-08-01
- Enrollment
- 1588
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.